Know before you go: #CTAD23 is set to kick off tomorrow, and we’ve prepared a host of activities and information sessions that you won’t want to miss. Find our schedule of events and activities in our latest press release. Read the press release for our CTAD plan of activities: https://ow.ly/qiXs50PZaNS #AlzheimersDisease #ClinicalTrials
Eisai U.S. Alzheimer’s Disease and Brain Health’s Post
More Relevant Posts
-
“Alzheimer’s can be measured in a lot of different ways, and this is something we’ve learned over time.” David Weisman, MD, shares what outcomes health care providers may look for in Alzheimer’s disease (AD) clinical trials. Watch the full video: https://ow.ly/YzXm50TzCN8 #AlzheimersDisease #neurology #clinicaltrials
View the replay here
-
“It’s important to recognize that there isn’t one correct measure of clinical meaningfulness.” Sharon Cohen, MD, FRCPC, explains how health care providers may derive clinical meaningfulness from Alzheimer’s disease (AD) clinical trials: https://ow.ly/PWFc50TzCGP #AlzheimersDisease #neurology #clinicaltrials
-
Are you a U.S. health care professional ready to advance your understanding of diagnosing Alzheimer’s disease (AD)? Sign up for the next ARIA MRI case-based learning session Thursday, October 10, at 1:00 PM ET. A neuroradiologist with advanced amyloid-related imaging abnormalities (ARIA) expertise will delve into cases demonstrating ARIA, severity grading, imaging pitfalls, and differential diagnosis. #AlzheimersDisease #dementia
-
It’s important that participants in Alzheimer’s disease (AD) clinical trials reflect the real-world population of people who are most likely to develop AD. Dung Trinh, MD, Chief Medical Officer at the Healthy Brain Clinic, explains why while highlighting the communities that have historically been underserved in this collaborative video series with Biogen. Learn more about Eisai’s commitment to AD research here: https://ow.ly/J5Ii50ThvwI #AlzheimersDisease #healthequity #neurology
-
Harald Hampel, MD, PhD, MSc and colleagues, including Suzanne Hendrix and Jeffrey Dage, published an article in Med by Cell Press featuring fluid biomarkers findings across 12 anti-amyloid beta clinical trials. The emerging biomarker data provide evidence on the impact of new therapies on the underlying pathophysiological processes of Alzheimer’s disease, supporting the presence of a disease-modifying effect. Read more: https://ow.ly/AU0A50TAm5Y #neurology #AlzheimersDisease #biomarkers #clinicaltrials
Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease
cell.com
-
On International Day of Older Persons, we’re highlighting neurologists’ crucial role in differentiating between normal aging and cognitive decline in Alzheimer’s disease (AD). We have resources for U.S. health care providers on key steps in assessing cognitive complaints: https://ow.ly/gvWa50TzCCZ #AlzheimersDisease #InternationalDayOfOlderPersons #EndAlz
